Integra LifeSciences Holdings Co. Receives Analysts' Consensus Rating of 'Reduce'

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have received a consensus rating of "Reduce" from eight analysis firms covering the stock, according to reports. Of these ratings, three analysts have rated the stock as a sell, while four have given it a hold rating, and only one analyst has issued a buy rating. The average target price for the stock over the next 12 months, based on the ratings from various brokerages, is set at $23.00.

Recent Analyst Comments

A few equities analysts have recently provided their opinions on IART shares. Morgan Stanley started coverage on Integra LifeSciences on December 2nd, giving it an "underweight" rating and setting a target price of $20.00. On the other hand, Argus upgraded the stock from a "hold" rating to a "buy" rating in their research report the same day.

Stock Performance Overview

As of a recent trading session, NASDAQ:IART saw an increase of $0.30, reaching a price of $21.99. In this session, the trading volume was 45,431 shares, which is significantly lower than its average volume of 1,044,262 shares. The stock has hit a 52-week low of $16.81 and a high of $35.45. With a market capitalization of $1.70 billion, its price-to-earnings ratio is currently at -244.27, while the price-to-earnings-growth ratio stands at 0.73, and the stock has a beta of 1.23. The company's financial ratios include a quick ratio of 0.73 and a current ratio of 1.20 with a debt-to-equity ratio of 0.79. The moving averages indicate a 50-day average of $23.78 and a 200-day average of $22.21.

Earnings Report Summary

Integra LifeSciences last released its earnings results on February 25th, where they reported earnings per share (EPS) of $0.97, surpassing the consensus estimate of $0.85 by $0.12. However, the company reported a negative net margin of 0.42% with a positive return on equity of 12.35%. The revenue for the quarter was $442.65 million, which was slightly below the analyst estimates of $445.15 million. In comparison to the same period last year, there was an increase of 11.5% in quarterly revenue. Analysts estimate that Integra LifeSciences will report an EPS of 2.45 for the current year.

Investments in Integra LifeSciences

Several large investors have recently altered their positions in IART. Intech Investment Management LLC acquired a new stake in Integra LifeSciences worth approximately $235,000 during the third quarter. Charles Schwab Investment Management Inc. increased its holdings by 15.3% during the same period, now owning 944,282 shares valued at $17.16 million following the purchase of 125,620 additional shares. Dynamic Technology Lab Private Ltd and Quantbot Technologies LP also made significant purchases, with the latter increasing their holdings by 230.5% to now own 72,351 shares, worth $1.31 million. BNP Paribas Financial Markets dramatically increased their stake by 824.5%, now owning 111,775 shares valued at $2.03 million. Overall, 84.78% of the stock is owned by hedge funds and institutional investors.

Company Overview

Integra LifeSciences Holdings Corporation is engaged in manufacturing and selling a variety of surgical instruments, neurosurgical products, and wound care items used in neurosurgery, neurocritical care, and otolaryngology. The company is divided into two segments: Codman Specialty Surgical and Tissue Technologies, offering products such as tissue ablation equipment, dural repair products, and surgical headlamps.

Integra, stocks, analysis